MEB braces itself for ‘hard Brexit’
This article was originally published in OTC Bulletin & The Rose Sheet
Strengthening cooperation with other European medicines authorities” is a priority for the Dutch medicines agency, the MEB, as it prepares for “the worst-case scenario” of a UK ‘hard Brexit’ from the European Union (EU) in March 2019, according to the agency’s president Hugo Hurts.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.